Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Mitophagy level by flow cytometry
研究概览
简要总结
Atherosclerosis (deposition of a plaque essentially composed of lipids on the artery walls) is a frequent condition and is a leading cause of death worldwide. In addition to the long-established risk factors such as age, hypertension, diabetes or sedentary lifestyle, it has been demonstrated that immune cells can participate in the genesis of atherosclerotic plaques through metabolic and mitochondrial reprogramming.
A non-invasive marker of this immune reprogramming has yet to be identified. Through the comparison of a group of atheromatous patients and a group of non-atheromatous patients, this study aims to evaluate this reprogramming phenomenon using a novel non-invasive method.
This monocentric interventional study will take place at the Dijon Bourgogne University Hospital and will include 50 patients divided into 2 groups: "atheromatous coronary patients" and "non-atheromatous patients". The duration of participation in this study is 1 month. This study is based on usually performed procedures. Only blood samples will be taken on a catheter usually used during any cardiac surgery in addition to the medical care that is provided during hospitalization.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- Person who provides oral consent
- •- Patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation
- •Patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation
- •No coronary lesion
- •No peripheral arterial disease (limbs, carotids, aortic aneurysm)
排除标准
- •Person not affiliated with national health care system
- •Medication that alters mitochondrial function (Chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil)
- •Person under a legal protection measure (curatorship, guardianship, tutorship)
- •Pregnant, parturient or breastfeeding women
- •Major unable to express consent
研究组 & 干预措施
Atheromatous coronary patients
patients scheduled for coronary artery bypass surgery with extracorporeal circulation
干预措施: Blood samples (Biological)
Atheromatous coronary patients
patients scheduled for coronary artery bypass surgery with extracorporeal circulation
干预措施: myocardial tissue samples (Procedure)
Atheromatous coronary patients
patients scheduled for coronary artery bypass surgery with extracorporeal circulation
干预措施: Data collection (Other)
Non-atheratomous patients
Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease
干预措施: Blood samples (Biological)
Non-atheratomous patients
Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease
干预措施: myocardial tissue samples (Procedure)
Non-atheratomous patients
Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease
干预措施: Data collection (Other)
结局指标
主要结局
Mitophagy level by flow cytometry
时间窗: Before the introduction of extracorporeal circulation.
Average fluorescence corresponding to PINK1-AF488 intracellular labelling (mitophagy checkpoint) in conventional (CD33+, CD66b-, CD14++, CD16-), intermediate (CD33+, CD66-, CD14++, CD16+), or non-conventional (CD33+, CD66b-, CD14+, CD16++) monocytes.
次要结局
未报告次要终点